WO2022107025 - UMLILO ANTISENSE TRANSCRIPTION INHIBITORS
National phase entry:
Publication Number
WO/2022/107025
Publication Date
27.05.2022
International Application No.
PCT/IB2021/060676
International Filing Date
17.11.2021
Title **
[English]
UMLILO ANTISENSE TRANSCRIPTION INHIBITORS
[French]
INHIBITEURS DE TRANSCRIPTION ANTISENS UMLILO
Applicants **
LEMBA BV
Inventors
TURCU, Gabriel Virgil
CIUREZ, Marius Andrei
BERRY, Stephanie
Priority Data
63/115,448
18.11.2020
US
63/235,890
23.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2848 | |
| EPO | Filing, Examination, Granting | 16749 | |
| Japan | Filing, Examination, Granting | 2605 | |
| South Korea | Filing, Examination, Granting | 2963 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
31,705
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A gapmer compound that is at least 91% complementary over its entire length to a Region A, B, C, D, E, or F of UMLILO (SEQ ID NO: 231), and that inhibits multiple acute inflammatory gene transcription regulated by the UMLILO long non-coding RNA, comprising: 5' wing sequence having from about 3 to about 7 modified nucleosides, a central gap region sequence having from about 6 to about 15 2'-deoxynucleosides, and a 3' wing sequence having from about 3 to about 7 modified nucleosides; wherein the gapmer nucleotides are each linked by phosphorothioate internucleoside linkages, phosphorothiolate internucleoside linkages, or combinations thereof throughout the gapmer compound; and wherein the modified nucleosides comprise 2'-methoxyethyl (2'-MOE) modification, a locked nucleic acid (LNA) modification, a 2'F-ANA modification, a 2'-O-methoxyethyl (2'OMe) modification, or combinations thereof.[French]
Composé gapmère complémentaire à au moins 91 % sur toute sa longueur à une région A, B, C, D, E ou F de UMLILO (SEQ ID NO : 231), et inhibant la transcription de gènes inflammatoires aigus multiples régulés par le long ARN non codant UMLILO, comprenant les éléments suivants : une séquence d'extrémité 5' ayant d'environ 3 à environ 7 nucléosides modifiés, une séquence de région centrale d'espacement ayant d'environ 6 à environ 15 désoxynucléosides d'extrémité 2', et une séquence d'extrémité 3' ayant d'environ 3 à environ 7 nucléosides modifiés ; les nucléotides du gapmère étant chacun liés par des liaisons internucléosidiques de type phosphorothioate, des liaisons internucléosidiques de type phosphorothiolate ou des combinaisons de celles-ci dans tout le composé du gapmère ; et les nucléosides modifiés comprenant une modification 2'-méthoxyéthyle (2'-MOE), une modification d'acide nucléique verrouillé (LNA), une modification 2'F-ANA, une modification 2'-O-méthoxyéthyle (2'OMe) ou des combinaisons de celles-ci.